ANCA glomerulonephritis and vasculitis

Keyphrases

• ANCA-associated Vasculitis 100%
• ANCA-associated Glomerulonephritis 100%
• Remission 33%
• Granulomatosis with Polyangiitis 33%
• Neutrophils 16%
• Targeted Therapy 16%
• Treatment Optimization 16%
• Small Vessels 16%
• Pathological Lesions 16%
• 50 Years Old 16%
• Immunomodulatory Therapy 16%
• Immunosuppressive Therapy 16%
• Autoimmune Response 16%
• Wegener 16%
• Pauci-immune 16%
• Model Evidence 16%
• Microscopic Polyangiitis 16%
• Geographic Influence 16%
• ANCA-negative 16%
• Renal Vasculitis 16%
• PR3-ANCA 16%
• Crescentic GN 16%
• MPO-ANCA 16%
• Proteinase 3 (PR3)-ANCA 16%
• Racial/ethnic Groups 16%
• Positive-negative 16%
• Myeloperoxidase-ANCA 16%

Medicine and Dentistry

• Vasculitis 100%
• Glomerulonephritis 100%
• ANCA Associated Vasculitis 100%
• Serotype 60%
• In Vitro 20%
• Targeted Therapy 20%
• Immunosuppressive Treatment 20%
• Prevalence 20%
• Myeloperoxidase 20%
• Granulomatosis with Polyangiitis 20%
• Microscopic Polyangiitis 20%
• Pauci-Immune 20%
• Autoimmunity 20%
• Myeloblastin 20%
• Diseases 20%
• Neutrophil 20%
• Eosinophilic Granulomatosis with Polyangiitis 20%

Immunology and Microbiology

• ANCA Associated Vasculitis 100%
• Glomerulonephritis 100%
• Vasculitis 100%
• Serotype 60%
• Autoimmunity 20%
• Immunosuppressive Therapy 20%
• Prevalence 20%
• Microscopic Polyangiitis 20%
• Neutrophil 20%
• Granulomatosis with Polyangiitis 20%
• Myeloperoxidase 20%
• Eosinophilic Granulomatosis with Polyangiitis 20%
• In Vitro 20%
• Proteinase 20%